From Harvard: Cost-effectiveness of viral hepatitis B & C treatment

Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):973-85. doi: 10.1016/j.bpg.2013.08.020. Epub 2013 Sep 27.

Cost-effectiveness of viral hepatitis B & C treatment.

Toy M.

Source

Department of Global Health and Population, Harvard School of Public Health, Harvard University, Boston, USA. Electronic address: mtoy@hsph.harvard.edu.

Abstract

With the availability of effective antiviral therapies for chronic viral hepatitis B and C, cost-effectiveness studies have been performed to assess the outcomes and costs of these therapies to support health policy. It is now accepted that treatment of active CHB is cost-effective versus no treatment, although there are a variety of options. And with the new developments around CHC treatment and diagnostic tools it is of interest to both the clinician and policy makers to know both the costs and effects of these choices. The purpose of this article is to provide the reader with an insight into the recent treatment developments and cost-effectiveness issues related to chronic hepatitis B and C treatment, and an overview of recent cost-effectiveness studies evolving around HBV and HCV therapy.